HIGHLIGHTS
SUMMARY
Adjuvant systemic therapy decision in early breast cancer is based on known prognostic and predictive factors and patient preferences. For HR-positive and HER2-positive cancers the standard therapy is chemotherapy followed by endocrine therapy plus a total of 1 year of trastuzumab treatment (I.A). During systemic therapy for early-stage cancer (neo) adjuvant chemotherapy should be chosen according to the treatment principles used for female breast cancer. Most male breast cancers are hormone-sensitive, and therefore endocrine therapy is one of the essential parts of adjuvant treatment. The principles governing systemic therapy . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.